United Therapeutics UTHR Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from United Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about United Therapeutics's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is United Therapeutics's return on assets?
- United Therapeutics (UTHR) reported return on assets of 17.8% in Q1 2026.
- How has United Therapeutics's return on assets changed year-over-year?
- United Therapeutics's return on assets increased by 4.7% year-over-year, from 17% to 17.8%.
- What is the long-term trend for United Therapeutics's return on assets?
- Over 4 years (2021 to 2025), United Therapeutics's return on assets has grown at a 15.2% compound annual growth rate (CAGR), from 39.2% to 69.1%.
- What does return on assets mean?
- How much profit the company squeezes out of everything it owns.
- How do you interpret return on assets?
- Higher means more productive assets. Unlike ROE, it is unaffected by leverage, so a wide ROE-minus-ROA gap flags a heavily levered balance sheet.
- How does return on assets compare across companies?
- Best compared within an industry — asset intensity varies enormously across sectors. Not meaningful for banks, whose assets are largely financial.